These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6978332)

  • 1. Asparenomycins A, B and C, new carbapenem antibiotics. V. Inhibition of beta-lactamases.
    Murakami K; Doi M; Yoshida T
    J Antibiot (Tokyo); 1982 Jan; 35(1):39-45. PubMed ID: 6978332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asparenomycins A, B and C, new carbapenem antibiotics. IV. Antibacterial activity.
    Kimura Y; Motokawa K; Nagata H; Kameda Y; Matsuura S; Mayama M; Yoshida T
    J Antibiot (Tokyo); 1982 Jan; 35(1):32-8. PubMed ID: 7068514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-19393 S2 and H2, new carbapenem antibiotics. IV. Inhibitory activity against beta-lactamases.
    Okonogi K; Nozaki Y; Imada A; Kuno M
    J Antibiot (Tokyo); 1981 Feb; 34(2):212-7. PubMed ID: 6975270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-lactamase inhibitory activities and synergistic effects of 5,6-cis-carbapenem antibiotics.
    Okonogi K; Harada S; Shinagawa S; Imada A; Kuno M
    J Antibiot (Tokyo); 1982 Aug; 35(8):963-71. PubMed ID: 6982889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases.
    Neu HC
    Am J Med; 1985 Nov; 79(5B):2-12. PubMed ID: 3907341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disc diffusion test for the determination of semi-quantitative substrate profiles of beta-lactamases.
    van de Klundert JA; van Gestel MH; van Doorn E; Mouton RP
    J Antimicrob Chemother; 1986 Apr; 17(4):471-9. PubMed ID: 3519561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition.
    Rotschafer JC; Ostergaard BE
    Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S15-22. PubMed ID: 7606585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Properties of Ro 13-99041 as a substrate and inhibitor of beta-lactamases.
    Then RL
    Chemotherapy; 1981; 27 Suppl 1():25-31. PubMed ID: 6972858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of beta-lactamases from Branhamella catarrhalis in relation to penicillinases produced by other bacterial species.
    Labia R; Barthelemy M; Le Bouguennec CB; Buu Hoi-Dang Van A
    Drugs; 1986; 31 Suppl 3():40-7. PubMed ID: 3488196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asparenomycins A, B and C, new carbapenem antibiotics. II. Isolation and chemical characterization.
    Shoji J; Hinoo H; Sakazaki R; Tsuji N; Nagashima K; Matsumoto K; Takahashi Y; Kozuki S; Hattori T; Kondo E; Tanaka K
    J Antibiot (Tokyo); 1982 Jan; 35(1):15-23. PubMed ID: 7040325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel carbapenem derivative SF2103A: studies on the mode of beta-lactamase inactivation.
    Yamaguchi A; Hirata T; Sawai T
    Antimicrob Agents Chemother; 1984 Mar; 25(3):348-53. PubMed ID: 6372682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of Sch 34343 against Gram-negative bacteria producing characterized beta-lactamases.
    Dornbusch K; Frolander F; Cacciapuoti AF; Naples L; Hare RS; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():85-97. PubMed ID: 3897175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sch 29482: stability and inhibitory potency towards beta-lactamases from Gram-negative bacteria.
    Pechère JC; Letarte R; Guay R; Asselin C; Morin C
    J Antimicrob Chemother; 1982 Feb; 9 Suppl C():123-32. PubMed ID: 6977528
    [No Abstract]   [Full Text] [Related]  

  • 14. β-Lactamases: A Focus on Current Challenges.
    Bonomo RA
    Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 27742735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of Ro 17-2301 (AMA-1080) with beta-lactamases.
    Then RL
    Chemotherapy; 1984; 30(6):398-407. PubMed ID: 6335074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of azthreonam and related monobactams with beta-lactamases from gram-negative bacteria.
    Bush K; Freudenberger JS; Sykes RB
    Antimicrob Agents Chemother; 1982 Sep; 22(3):414-20. PubMed ID: 6982680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. beta-Lactamases of increasing clinical importance.
    Bush K
    Curr Pharm Des; 1999 Nov; 5(11):839-45. PubMed ID: 10539991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of formylamino- and methoxy-substituted beta-lactam antibiotics with beta-lactamases.
    Okonogi K; Sugiura A; Kuno M; Ono H; Harada S; Higashide E
    J Antibiot (Tokyo); 1985 Nov; 38(11):1555-63. PubMed ID: 3878359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 7 alpha-formylamino substituent confers beta-lactamase-inactivating potency on 1-oxacephalosporins.
    Murakami K; Doi M; Yoshida T
    Antimicrob Agents Chemother; 1986 Sep; 30(3):447-52. PubMed ID: 3490828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanism of enzymatic resistance to beta-lactam antibiotics].
    Philippon A; Paul G; Nevot P
    Presse Med; 1986 Dec; 15(46):2290-6. PubMed ID: 2949270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.